TOPLINE Oral brepocitinib, a first-in-class oral, selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, improved cutaneous disease activity, pruritus, and skin-related quality of life (QOL) through 52 weeks in adults with dermatomyositis in the prespecified secondary analysis of a phase 3 trial. METHODOLOGY Researchers conducted a prespecified secondary analysis of the 52-week…
Read More
Brepocitinib Controls Skin Disease in Dermatomyositis
